Olaparib monotherapy (BRCA-mutant HER2- breast: metastatic OR adjuvant high-risk early)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-OLAPARIB`

ID	`REG-OLAPARIB-BREAST`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-BREAST-METASTATIC-2024` `SRC-NCCN-BREAST-2025`

Notes

OlympiAD: PFS benefit in BRCA-mutant HER2- metastatic. OlympiA: iDFS + OS benefit in adjuvant BRCA-mutant high-risk early breast (TNBC stage II+ OR HR+/HER2- pCP-3 OR ≥4 nodes). Germline BRCA testing required pre-start.

Used By

Handbook Chapters

HB-BREAST-HER2-POS-MET-1L - HER2+ metastatic breast cancer: first-line reasoning
HB-BREAST-HR-POS-HER2-NEG-1L - HR+/HER2- metastatic breast cancer: first-line reasoning

Indication

IND-BREAST-BRCA-POS-MET-PARPI - IND-BREAST-BRCA-POS-MET-PARPI
IND-BREAST-TNBC-2L-BRCA-OLAPARIB - IND-BREAST-TNBC-2L-BRCA-OLAPARIB
IND-BREAST-TNBC-2L-BRCA-TALAZOPARIB - IND-BREAST-TNBC-2L-BRCA-TALAZOPARIB